Recombinant hIL-10 and vIL-10 inhibit VEGF-induced angiogenesis.

The 1000 units vIL-10 (A) and hIL-10 (B) were incorporated in slow release pellets in the absence (■) and in the presence (○) of recombinant VEGF-165 (200 ng per pellet), VEGF-165 alone (●). The results represent mean ± SEM of at least 4 independent implants. Representative pictures of VEGF-165–induced neovascularization in the absence (C), and in the presence of hIL-10 (D). Photographs were taken at day 15.